Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Fiche publication
Date publication
octobre 2018
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
Tous les auteurs :
Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide due to the lack of effective treatments. Chemoprevention in high-risk patients is a promising, alternative strategy. In this study, pioglitazone was investigated for its ability to prevent hepatocarcinogenesis in two rodent models of cirrhosis.
Mots clés
AMPK, Chemoprevention, Fibrosis, HCC, NASH, PPARγ
Référence
J. Gastrointest. Surg.. 2018 Oct 26;: